Update on New Federal Regulations Affecting Clinical Pathology Laboratories: Stage 2 ‘Meaningful Use’ Rules Top the List

Final Stage 2 rules give providers another year to meet Stage 1 ‘meaningful use’ criteria and shorten Stage 2 requirements from one-year to just 90 days Clinical laboratory managers and pathologists may be interested to know that, over the fall months, the U.S. Department of Health and Human Services (HHS) released three new rules that affect users of health information technology (HIT). One rule covers Stage Two of Meaningful Use and includes guidance on how providers should address the need...

HHS and CMS Team Up to Propose New Rule to Give Patients Direct Access to their Clinical Pathology Laboratory Test Results

Draft language of new rule would change existing requirements on access to medical laboratory test results as defined in CLIA and HIPAA laws Big changes lie ahead in how clinical laboratories and pathology groups must give patients access to their medical laboratory test results. Last week, federal agencies published a draft rule that specifies how patients or their authorized representatives are to be given direct access to their medical laboratory test results. This draft rule was made...

Clinical Laboratories and Pathologists Dodge a Bullet as CMS Publishes Proposed Repeal Rule Dealing with Physician Signature Requirement on Paper Requisitions for Lab Tests

Proposed repeal rule was published in yesterday’s Federal Register Yesterday, pathologists and clinical laboratory managers got an early Fourth of July present. That’s because the federal Centers for Medicare and Medicaid Services (CMS) published the proposed rule that repeals the requirement that paper requisitions for medical laboratory tests must have the physician’s signature. This rule had been mandated by the 2011 Medicare Physician Fee Schedule Rule that was to take effect on January 1,...
;